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ABSTRACT 
BACKGROUND:   
Magnesium has a very important role in the pathogenesis of 
myocardial infarction as well as its complications such as 
arrhythmias, CCF.  Magnesium has a role in improving myocardial 
metabolism, in inhibiting calcium accumulation and prevention of 
myocardial cell death.  It also has a role to maintain the vascular 
tone after loaded cardiac output, peripheral vascular resistance and 
reduces cardiac arrhythmias and improving lipid metabolism.  
Magnesium also reduces damage caused by oxygen derived free 
radical, improves endothelial function and prevents platelet 
aggregation and adhesion. 
OBJECTIVE 
To know the relationship between incidence of arrhythmia 
and serum magnesium levels in patients with acute myocardial 
infarction in KMC.   
METHODS 
By using simple random methods 50 patients admitted in 
Cardiology Department of KMC with acute myocardial infarction 
was selected over a period of six months. 
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RESULTS 
Significant difference have been noted in the incidence of 
arrhythmia between hypomagnesemics and normomagnesemics 
people in myocardial infarction. 
CONCLUSION 
Patients with low magnesium levels are prone to develop 
arrhythmias and risk factors like hypertension, diabetes increases 
the risk of arrhythmias in CAD patients.  
KEY WORDS 
Magnesium, myocardial infarction, arrhythmias. 
 3 
INTRODUCTION  
Since a long time we know that for normal growth and 
function of biological forms inorganic salts are required.  Thus, 
Pasteur (1860) proved that yeast can grow only if the culture 
medium has inorganic compounds.  In human body there is a 
tendency to maintain fluid balance both as a whole as well as 
between the three compartments.    
This is achieved by intricate play of electrolytes, 
hemodynamics and other external forces.  At present world, mineral 
metabolism is under rapid expansion.  It has come to evidence that 
not only carbohydrates, proteins and fat, but also minerals are 
necessary to life.  Now the significance of not only vitamins and 
other organic substances but also minerals is under investigat ion. 
Magnesium has a very important role in pathogenesis of acute 
myocardial infarction as well as its complications like arrhythmias 
and CCF.
1-5
   
Magnesium has a very important role in other cardiovascular 
diseases also. 
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Magnesium ions play a role in maintaining the functional 
integrity of the  myocardium.  
Investigations showed that magnesium levels are decreased in 
the initial phases of AMI and also the findings directly correlated with 
occurrence of complications like arrhythmias.  There are evidences to 
show that myocardial magnesium concentration are found to be very 
low in patients with sudden cardiac death due to ischemia.  The factors 
responsible for this are the role of magnesium in ventricular fibrillation 
which results in sudden death in IHD patients and coronary vasospasm 
due to magnesium deficiency
6-9
.  The eighth most common element in 
earth is magnesium and is usually tied up with other mineral deposits 
such as magnesium carbonate, dolomite.  The autonomic mass of 
magnesium is 24.305, specific gravity is 1.738 and boiling point is 
1090 degree C.   
It is a group II element in periodic table.  Magnesium salt is 
soluble in water.   
Role of magnesium is important for both plants and animals.  
Magnesium is the  central ion of the chlorophyll and is a fourth 
most abundant cation in vertebrates.   
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Other uses are technical and medical applications like alloy 
production, fertilizers  and healthcare.
10
  Antacids and laxatives 
also utilizes magnesium salts. 
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REVIEW OF LITERATURE  
Myocardial infarction is a syndrome as a result of injury to 
myocardial tissue due to imbalance between perfusion and demand. 
Main cause being coronary atherosclerosis with a superimposed 
coronary thrombus. 
In 2007 expert consensus document redefined acute MI as 
detection of a rise and fall in cardiac troponin with at least one 
value above  the 99
th
 percentile of the upper reference limit (URL) 
together with evidence of ischaemia. 
Ischaemia can be either symptomwise, ECG changes of new 
ischaemia or development of pathologic Q waves in ECG or 
imaging evidence of infarction. 
Included in this definition were sudden cardiac death and 
evidence of myocardial ischaemia (new ST elevation LBBB or 
coronary thrombus) and biomarker elevation > 3 x URL for post –
PCI patients, 5 x URL-for post CABG patients. 
Documented stent thrombosis was also included in this new 
definition. 
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Established MI was defined as anyone of the following criterion: 
a) Development of new pathologic Q waves on serial ECGs 
b) Imaging studies showing MI 
c) Pathologic findings of healed or healing MI. 
CLINICAL CLASSIFICATIONS OF DIFFERENT  
TYPES OF MI
11 
Type-I  Spontaneous MI related to ischemia from a coronary 
plaque rupture/dissection. 
Type-II  MI due to ischaemia resulting from increased oxygen 
demand or decreased supply. 
Type-III  Sudden cardiac death, symptoms of ischaemia, new ST 
elevation or LBBB or coronary thrombus. 
Type-IV a  MI associated PCI 
Type-IV b MI associated stent  
Type-V  MI associated CABG 
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CLINICAL DIAGNOSIS  
If a patient is suspected to have chest pain of cardiac or igin 
ECG should be taken within 10 minutes.  If ECG has evidence of 
acute ST-segment elevation or new LBBB, emergent reperfusion 
treatment with PCI or fibrinolysis is indicated. 
If patient has history suggestive of cardiac chest pain and no 
EGC criteria for reperfusion therapy then patient might have 
unstable angina or NSTEMI. 
SIGNS AND SYMPTOMS  
Crushing substernal chest pain described as squeezing or 
constriction pain which radiates to left shoulder associated with an 
impending sense of doom. 
In postoperative patients, elderly and in diabetic MI can occur 
without chest pain. 
If there is sudden pain which is tearing or knife like and 
radiates to back aortic dissection should be considered. 
Associated Symptoms 
Dyspnoea, diaphoresis, lightheadedness, fatigue, palpitations, 
acute confusion, nausea, vomiting and indigestion.  
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Gastrointestinal symptoms are common in IWMI. 
Physical examination does not play a much role in MI but is 
important for risk stratification or to rule out other mechanical 
complications. 
DIFFERENTIAL DIAGNOSTIC CONSIDERATIONS FOR ST-
SEGMENT ELEVATION MYOCARDIAL  
infarction 
 
Comorbid 
ischaemia 
ST elevation but no 
ischaemia 
Chest pain but no 
ischaemia 
Aortic dissection 
Systemic arterial 
embolism 
Hypertensive Crisis 
Aortic stenosis 
Cocaine use 
Arteritis 
Early repolarization 
LVH 
LBBB 
Hyperkalaemia 
Brugada syndrome 
 
Aortic dissection 
Myopericarditis  
Pleuritis 
Pulmonary embolism 
Costochondritis 
GI disorders 
LABORATORY INVESTIGATIONS  
Troponins – Troponin T and Troponin I are useful in the 
diagnosis and management of unstable angina and NSTEMI 
because of their high sensitivity, it can interpreted at bedside 
rapidly available universally helps in detection of myocardial 
necrosis.
12 
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Troponin elevation in absence of IHD is seen in  
a) congestive heart failure  
b) HOCM 
c) Aortic dissection 
d) Cardiac contusion 
e) Pulmonary embolism  
f) Acute neurologic disease  
g) Drug toxicity  
CREATININE KINASE  
Appreciable rise in CK levels takes 4-6 hours. 
CK – CK-MB is elevated in pericarditis and myocarditis 
which may cause diffuse ST-segment elevation.
13 
MYOGLOBIN 
Peak level is seen in 1-4 hours which allows diagnosis of 
acute MI. 
There is lack of cardiac specificity which limits clinical 
utility of myoglobin. 
Diagnostic testing includes ECG changes and 
echocardiography. 
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RISK STRATIFICATION    
TIMI Risk Model for prediction of short-term mortality in 
ST-segment elevation MI patients. 
HISTORY  
Age 65-74 years 2 points  
Age > 75 years 3 points  
Angina /DM/HTN      1 point  
PHYSICAL EXAMINATION  
HR > 100 bpm 2 points  
SBP < 100 mgHG 3 points 
Killip class II-IV 2 points 
Weight < 67 kg 1 point  
PRESENTATION  
Anterior ST elevation/LBBB time to treatment > 4 h 1 point  
Time to treatment > 4h 1 point  
TIMI RISK SCORE = TOTAL POINTS (0-14) 
a) TIMI score of 9 or more predicts 30day mortality of  35% 
approximately. 
b) TIMI score of 0 or 1 has 30 day mortality rate less than 2%.  
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c) The predictors for poor prognosis are advanced age, HTN, Killip 
Class II-IV at presentation, DM, weight and time to treatment of 
more than 4 hours. 
THERAPY 
ST elevation MI is the most critical clinical condition in 
cardiology but also most satisfying when it is managed 
appropriately.  Present availability of treatment measures can save 
many lives and helps to restore in normal cardiac function.  
Cardiac Markers - reduced blood flow to the myocardium will 
lead to cardiac Ischaemia.  When ischaemia is prolonged (20-40 
minutes or more) it leads to Injury.  Death of the injured 
myocardial cells is infarction and they release macromolecules 
which can be detected in the bloodstream.  Cardiac markers are  
CK-MB isoforms, CK-MB, myoglobin and cardiac troponins I and 
T.  CK-MB  
Isoforms and cardiac troponins I and T are very specific to 
cardiac necrosis, and they can be detected only after 4-6 hours of MI. 
HIGH RISK STEMI  
a) ST elevation MI with any of the following features: 
a. Previous history of MI 
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b. New LBBB 
c. Ejection fraction less than 35% 
d. Extensive ST elevation  
e. Killip class > 2 
b) Anterior wall MI with ST elevation more than 2mm in 2 or 
more leads 
INDICATIONS FOR DES USE IN STEMI 
1) Diabetes mellitus  
2) Long lesion in culprit vessel  
3) Smaller vessel size 
4) Proximal occlusion of LAD 
5) Patients ability to comply with prolonged double platelet 
therapy. 
STRATEGY FOR REPERFUSION  
It is indicated for all patients with history of chest pain for 
less than 12 hours and with ST elevation or new onset LBBB, any 
ECG evidence of ongoing ischaemia and symptoms for more than 
12 hours.  Reperfusion therapy with PCI should be considered in 
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stable patients with more than 12-24 hours of symptoms.  In stable 
patients with no angina and PCI is not indicated after 24 hours. 
ASSESSMENT OF REPERFUSION OPTION FOR STEMI 
PATIENT  
Step-1: 
 Time and Risk assessment. 
Time since the onset of systems. 
Risk of STEMI. 
Time required for transportation to a PCI lab. 
Risk of fibrinolysis. 
Step-2 
To identify if fibrinolysis or invasive strategy is needed. 
Within three hours of presentation and there is no delay for 
invasive procedure, both are equally beneficial. 
Fibrinolysis is generally preferred under the following 
conditions:
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1) Presentation of less than 3 hours of onset of symptoms and 
there is a delay to invasive procedure. 
2) Catheterization lab is not available or occupied, lack of 
accessibility to a PCI lab, any difficulty in vascular access.  
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3) Delay to invasive strategy either prolonged door to balloon 
time or medical contact to balloon or door to balloon is more 
than 90 minutes.   
Invasive strategy is preferred under following conditions 
1) Availability of skilled PCI lab with surgical facilities.  
2) High risk from STEMI either cardiogenic shock or Killip 
class > 3. 
3) Bleeding manifestations or ICH. 
4) Late presentation more than 4 hours. 
5) Situations were diagnosis of STEMI is doubtful. 
GENERAL MEASURES  
Routine measures include oxygen supplementation, analgesics 
like morphine 2-4  
Mg IV which can be increased up to 8 minutes at 5-15 
minutes of interval as per requirement.   
Fibrinolysis:  Absolute contraindications  
1) Features of aortic dissection. 
2) History of ICH 
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3) Ischaemic stroke less than three months of duration 
except for acute ischaemic stroke of less than 3 hours. 
4) Any intracranial neoplasm. 
5) Arteriovenous malformation. 
6) Bleeding diathesis. 
7) Head or facial trauma within three months. 
RELATIVE CONTRAINDICATIONS   
1) Uncontrolled hypertension. 
2) Severe hypertension of more than 180 mmHg of SBP and 
DBP more than 110 mmHg.  CPR or major surgery within 
less than three weeks. 
3) Noncompressive vascular punctures. 
4) Recent internal bleeding (2-4 weeks). 
5) Prior history of any allergic reactions to streptokinase. 
6) Active peptic ulcer. 
7) Pregnancy. 
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8) Current use of anticoagulants:  Higher the INR, more risk of 
bleeding. 
FIBRINOLYTIC THERAPY DOSAGE 
Streptokinase:  1.5 MU IV over 30-60 minutes. 
Tenecteplase:  If < 60, give 30 mg single IV bolus; if 60-69 
kg, give 35 mg single IV  
Bolus; if 70-70 kg, give 40 mg single IV bolus; if 80-89 kg, 
give 45 mg single IV  
Bonus; if > 90 kg, give 50 mg single IV bolus. 
Reteplase:  10 U IV over 2 minutes, repeat after 30 minutes. 
ANTIPLATELET AND ANTITHROMBIN CO-THERAPIES 
ALONG WITH FIBRONYLSIS  
Aspirin 125-325 mg of loading dose should be chewed by the 
patient.   
Maintenance therapy 75 mg per day. 
Clopidogril 300 mg- if age < 75 years loading dose. 
If age > 75 years-75 mg, maintenance dose of 75 mg per day should 
be given for a minimum period of one year.  
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Enoxaparin- Age <75 years and creatinine < 2.5 mg/ml should 
be given 30 mg bolus followed by 15 minutes later 1 mg/kg every 
12 hours subcutaneous dosage until the time of discharge or for a 
maximum period of eight days. 
Heparin- 60 units per kg IV bolus to a maximum of 4000 
units followed by IV  
Infusion of 12 units per kg to a maximum of 1000 units per 
hour. 
aPT has to be maintained at 50-70 seconds and should be 
monitored at 3, 6, 12/24 hours. 
Fondaparinux- 25 mg IV bolus followed by 2.5 mg s.c. its 
dose once daily up to eight days. 
Nitroglycerin is available as sublingual tablets,IV form, 
aerosol spray. 
INDICATIONS 
1) Antianginals if ischaemic pain is suspected. 
2) In acute phase of AMI, large AWMI, CHF, persistent or 
recurrent ischaemia, hypertension. 
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3) Beyond 48 hours doses continued for patients with recurrent 
angina and persistent pulmonary congestion. 
4) In case of hypertension urgency. 
PRECAUTIONS AND CONTRAINDICATIONS 
It has to be limited in AMI patients to a fall of systolic BP by 
10% in normotensive, 30% drop if hypertensive and avoid drop 
below 90 mmHg.Should not be mixed with other drugs.  Patient 
have to lie down or sit while getting the medication.  The aerosol 
spray should not be shaken as it affects the metered dose. 
CONTRAINDICATIONS 
1) Bradycardia. 
2) Right ventricular infarction. 
3) Hypotension. 
DOSAGE OF IV INFUSION 
12.5-25 mcg of IV bolus if no sublingual or spray given. 
Infusion at rate of 5-20 mcg/min.  In emergency IV is a route 
of choice.  Titration of dose is important to achieve effects.  Drug 
has to be diluted in D5 or NS. 
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Sublingual route - 0.3-0.4 mg of one tablet repeated every 5 
minutes. 
Aerosol spray 1-2 spray for 0.5-1 second at an interval of 5 
minutes, maximum is 3 sprays within 15 minutes.  
BETA-BLOCKERS  
All myocardial infarction patients should be given the benefit 
of beta-blockers if there is no contraindication irrespective of 
primary PCI.   
In case of tachyarrhythmia or hypertension IV beta-blockers 
is preferred.   
CONTRAINDICATIONS FOR BETA-BLOCKERS  
1) Low output state. 
2) There is risk of cardiogenic shock. 
3) Heart failure. 
4) Others relative contraindications are prolonged PR interval, 
active asthma, any AV block, reactive airway disease. 
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DOSAGE  
Esmolol 500 mcg/kg over 1 minute followed by 50 mcg/kg 
over 4 minutes as IV injection.  Maintenance dose is at 60-200 
mcg/kg/min infusion. 
Metoprolol- 2.5-5 mg IV over 2 minutes can be given up to 
three doses. 
Oral 50 mg 6th hourly for the first two days and then 100 mg 
12th hourly has to be continued. 
Atenolol- 1 mg/min as IV dose to a maximum of 5-10 mg. 
Propranolol-0.15 mg/kg by IV route. 
ACE INHIBITORS 
All patients with anterior infarction should be given ACE 
inhibitors within 24 hours orally unless there is any 
contraindications. 
DOSAGE  
1)  Captopril 6.25 mg initially, 12.5 in 2 hours followed by 25 
mg at 10-12 hours, target dose is up to 50 mg twice a day. 
2) Lisinopril- 5 mg initially up to 10 mg every day. 
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3) Ramipril-2.5 mg twice a day up to 5 mg twice a day if 
tolerated. 
4)  Valsartan- 20 mg up to 160 mg twice a day. 
5)  Losartan-12.5 mg initially followed by 50 mg daily.  
6) Eplerenone-12.5 mg initially followed by 50 mg every day.  
PRIMARY PCI 
Should be performed in STEMI patients or with new LBBB if 
the patient can undergo PCI within 12 hours of symptoms, and 
balloon inflation within 90 minutes of presentation. 
SPECIFIC CONSIDERATION:
15 
The goal of PCI is to be performed as quickly as possible 
with a medical contact- to-balloon or door-to-balloon of less than 
90 minutes.  
For symptoms less than 3 hours PCI should be performed 
within the first 1 hour, in new onset LBB patients with age less 
than 75 years, in pulmonary edema CHF patients within 12 hours 
onset of symptoms.   
Rescue PCI is a procedure performed in a coronary artery that 
remains occluded in spite of fibrinolytic therapy and if there is less 
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than 50% resolution of ST segment elevation after 60-90 minutes of 
the start of fibrinolytic therapy.   
Introcoronary medications during primary PCI. 
Medications Dosage 
Nicorandil 500 mcg single bonus to a total of 10 mg  
Eptifibatide 180 mcg/kg x 2 doses 
Verapamil 200 mcg as a single bolus to a total of 1 mg  
Epinephrine 50-200 mcg 
Nitroprusside 100 mcg single bonus to a total of 1 mg 
Titrofiban 10 mcg/kg (IC) followed by 0.15 mcg/kg/min 
Streptokinase 250kU over 3 min 
Adenosine 12 mcg as a single bolus to a total of 4 mg 
Diltiazem 200 mcg as a single bolus to a total of 5 mg 
Abciximab 0.25 mg/kg (IC) followed by 0.125mcg/kg/m for 
12h (IV) 
Nicardipine 200 mcg as a single bolus to a total of 1 mg 
IC: intracoronary IV: Intravenous 
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TIMI ANGIOGRAPHIC FLOW GRADING 
16 
Epicardial  
blood flow 
TIMI flow grades (TFG) 
0 Absence of anterograde after occlusion  
1 Contrast agent passes through occluded area  without 
opacifying whole length of artery by the end of injection   
2 Contrast agent opacifies the whole artery but is  
very slow in nonculprit arteries or proximal to  
occluded portion of the artery  
3 Normal anterograde flow as in nonculprit artery or  
proximal to occlusion  
4 Anterograde flow and clearance of the contrast is  
faster compared to nonculprit arteries   
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TIMI MYOCARDIAL PERFUSION GRADING
17
  
Micro 
vascular 
flow 
TIMI Myocardial Perfusion Grades (TMPG) 
0 Absence or minimum blush of the myocardium in the  
distribution section of  the culprit artery 
1 Persistent myocardial blush; the contrast agent enters 
the microvasculature, but it does not normally pass to 
the venous phase:"persistent stain" is detected at the 
beginning of the next injection (> 30s) 
2 Delayed blush and washout of the myocardium: the  
myocardial stain is evident (maximum level or 
minimum decline inintensity) by the end of the 
injection (3 heart beats for washout) 
3 Normal blush: entry and exit of the contrast agent 
from the microvasculature at normal speed (total or 
high washout of the dye within 3 heart beats 
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COMPLICATIONS OF ACUTE MYOCARDIAL 
INFARCTION 
1) ISCHAEMIC  
a. Reinfarction  
b. Angina  
c. Extension of the infarct 
2) MECHANICAL 
a. Cardiogenic shock  
b. Heart failure 
c. Aneurysms/cardiac rupture 
d. Mitral valve dysfunction  
3) ARRHYTHMIC  
a. Atrial arrhythmias  
b. Ventricular arrhythmias  
c. Sinus node dysfunction 
d. atrioventrcular node dysfunction  
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4) EMBOLIC COMPLICATIONS  
a. Central nervous system or peripheral embolisation 
5) INFLAMMATORY  
a. Pericarditis  
ISCHAEMIC COMPLICATIONS 
a)  Extension of the infarct is nothing but increase in the 
amount of myocardial necrosis within the infarct zone of 
myocardial infarction.  Incidence of reocclusion of the artery is 
about 5-10% at the time of discharge and increases to 25-30% at 
one year.
44 
Hence such patients have poor prognosis.
45-46 
Reinfarction is usually seen in patients with diabetes mellitus 
or old CAD.  With the advent of PCI and stent surgery reinfarction 
rate has substantially decreased to about 3% during first 90 days 
following MI.
47 
PATHOPHYSIOLOGY  
When the infarcted artery reoccludes it leads to reinfarction 
but reocclusion of the infarcted artery does not always lead to 
reinfarction due to abundance of collateral circulation.  Reocclusion 
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following post fibrinolytic therapy  is 5-10% and has a poor 
prognosis.  When PCI is done the rate is much lower. 
The pathophysiology of post infarction angina is plaque 
rupture similar to unstable angina and the management is same as 
unstable angina.  Echocardiography is a diagnostic method of 
choice. 
SIGNS AND SYMPTOMS 
1) Continuous chest pain 
2) Elevated creatinine kinase level  
TREATMENT  
Pharmacological therapy with heparin, nitroglycerin, beta 
blockers and statins are usually given to patients who have had MI 
and are presently experiencing ongoing ischaemic symptoms.
48
  
Depending on clinical situation antiplatelet therapy can be 
given and intraaortic balloon pump is inserted promptly in 
haemodynamically unstable patients.  
EMBOLIC COMPLICATIONS  
Incidence of embolism is less than 2% and maximum 
incidence is with AWMI patients.  Large AWMI may have up to 
60% incidence of mural thrombus.
49-50 
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PATHOPHYSIOLOGY  
Most commonly emboli originates from left ventricle and the 
cause being wall motion abnormalities or aneurysms.  
Atrial fibrillation along with ischaemia can lead to systemic 
embolisation. 
SIGNS AND SYMPTOMS  
Stroke is the most common clinical presentation.  Other 
features are limb ischaemia, mesenteric ischaemia or renal 
infarction.  Usually systemic embolic occurs within 10 days of 
acute myocardial infarction.  Limb ischaemia presence with cold 
clammy painful pulseless extremities.  Features of renal infarction 
are pain in the flank, haematuria and raising urea creatinine.  
Mesentric ischaemia presence with severe abdominal pain, 
bloody diarrhea and anorexia. 
MANAGEMENT 
Heparin through IV route should be given immediately in the 
absence of any active bleeding and the target APTT time should be 
50-70 seconds and heparin has to be continued until Warfarin gets 
into therapeutic action. 
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Warfarin has to be continued for at least 3-6 months with INR 
maintain at a range of 2-3.  Patients with large akinetic areas 
detected by echo should also be given Warfarin for 3-6 months. 
ARRHYTHMIAS IN MI  
Literature shows that 90% of people with MI develop some of 
arrhythmia either immediately or later.
 
Arrhythmias occur within 24 hours in 25% of patients.  Risk 
of ventricular fibrillation is more with STEMI than NSTEMI most 
peri-infarct are complications of myocardial infarction broadly 
classified into arrhythmia complications. 
Sinus tachycardia – causes increased sympathetic activity 
which may lead to transient HTN or hypotension, tachycardia 
increases the diastole length and reduces coronary flow which leads 
to worsening of myocardial ischaemia. 
Causes of persistent tachycardia are 
1) Pain 
2) Anxiety  
3) Heart failure 
4) Hypoxia 
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5) Hypovolemia 
6) Pericarditis  
7) Pulmonary embolism  
8) Anaemia  
In AMI patients treating sinus tachycardia plays an important 
role.   
 Treatment includes: 
Analgesics, diuresis for heart failure, oxygenation, volume 
repletion for hypovolemia, beta blockers for ischaemia, anti -
inflammatory measures. 
PAC - may be a preceding event of SVT, atrial fibrillation or 
atrial flutter.   
No specific therapy is indicated.    
Pathogenesis is inflammatory associated with pericarditis or 
atrial distention due to enhanced  left ventricular diastolic pressure. 
PAROXYSMAL SVT 
Incidence is less than 10%. 
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Management:  Adenosine can be used if there is no 
hypotension.   
In the absence of heart failure/hypotension synchronized 
electrical cardioversion is needed. 
Atrial flutter - occurs in 5% or less usually it is temporary and 
is due to sympathetic overstimulation of atria. 
Atrial fibrillation - incidence in 10-15% in acute myocardial 
infarction  patients.  During initial hours of  MI cause of AF is LV 
failure, RV infarction  ischaemic injury to atria.  Other causes of 
AF in MI are pericarditis, other  condition which increases LA 
pressure.   
AF in MI increases the risk of stroke, mortlity or patients 
synchronized electrical cardioversion in the treatment.  
Other modalities of treatment are IV Amiadarone, Digoxin, 
Beta blocker, if  no hypotension Diltiazem. 
Atrial fibrillation and atrial flutter increases risk of 
thromboembolism hence anticoagulation therapy with Heparin is 
needed if no contraindication. 
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Accelerated junctional rhythm  is most common in IWMI 
caused by  increased automatically of junctional tissue. 
Treatment is to correct the underlying ischaemia.  
BRADYARRHYTHMIAS  
A) Sinus bradycardia is common in inferior and posterior wall 
infarction. 
Pathogenesis is stimulation of cardiac vagal afferent receptors 
leading to efferent cholinergic stimulation of the heart which 
results in bradycardia  and hypotension. 
Treatment is not urgent in case of isolated sinus bradycardia 
with heart rate  > 40 bpm. 
Treatment is mandatory with atropine sulfate 0.5-1 mg every 
3-5 minutes to a maximum of 0.03-0.04 mg/kg if HR <406 pm. 
If atropine is ineffective additional treatment with dopamine 
5-20  mg/kg/min IV, dobutamine or epinephrine is used. 
External pacemaker is needed for resistant bradycardia.  
B) Junctional bradycardia - is a protective phenomenon with a 
rate of 35-60 bpm in IWMI patients.  No specific treatment is 
needed. 
First degree AV block- prolongation of PR interval of more 
than 0.2 seconds is the feature in ECG.  
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Incidence is 15%, and most common in IWMI patients.  
Treatment is unnecessary unless there is hemodynamic 
compromise.   
Atropine is the treatment of choice for first degree AV block 
with  hypotension.   
Second degree AV block - Mobitz type 1 is associated with 
narrow QRS complex and his most often associated with IWMI.  
Incidence is around 10% in acute myocardial infarction patients.  
Treatment is rarely required. 
Mobitz type 2 AV block is associated with poor prognosis as 
it has tendency to progress to complete heart block.  A temporary or 
permanent pacemaker must ultimately be placed. 
Third degree AV block or complete heart block - occurs in 15% 
of patients  with MI.  It may occur either with AWMI or IWMI 
patients.  The development of block with inferior infarction is 
gradual progressing from first degree or type 1 second degree 
block.   
The level of block in most patients is supranodal or intranodal 
and escape rhythm is usually stable with QRS complex being 
narrow and rate more than 40 bpm.   
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In 30% of patients the level of block is below Bundle of Hiss 
which results in escape rhythm and heart rate less than 40 bpm and 
a broad QRS complex.   
IWMI with complete heart block usually responds to Atropine 
and in most patients the block resolves spontaneously within few 
days.  Prognosis of patients with inferior wall MI with complete 
heart block is good compared to AWMI patients with CHB as they 
may require permanent pacemaker. 
Intraventricular blocks - conduction from Bundle of His is 
transmitted  through the anterior division of the left bundle, the 
posterior division of left bundle and the right bundle.  An 
abnormality of electrical conduction in any of these bundle is seen 
in 15% of AMI patients.   
Isolated left anterior fascicular block incidence is about 3-5% 
and rarely progresses to complete heart block.  The blood supply of 
right bundle branch is from left anterior descending artery.  Hence 
in about 2% of AMI patients new RBBB is seen. 
Rarely it progresses to complete heart block.  In anterior MI 
patients with a new RBBBthe cause of death is mostly cardiogenic 
shock. 
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Bifascicular block is a combination of RBBB with LAFB 
usually occurs with occlusion of proximal LAD.  There is more 
chance of development of complete AV block.  Bifascicular block 
with first degree AV block is known as  trifascicular block.  40% 
patients may progress to complete heart block.
18 
VENTRICULAR ARRHYTHMIAS  
PREMATURE VENTRICULAR CONTRACTIONS  
Previously PVCs were considered as indicators of impending 
ventricular arrhythmias but these days VPCs usually occur in MI 
patients without any further progression to arrhythnmias.  
Prophylactic treatment is not indicated instead we should aim to 
correcting any electrolyte of metabolic abnormalities as well as 
identifying and treating  recurrent ischaemia.   
Accelerated idioventricular rhythm is seen in about 20% of 
AMI patients.   
ECG is characterized with a wide QRS complex with a 
regular escape rate which is faster than atrial rate but less than 100 
bpm.  They are short and transient and terminate spontaneously.  
Mechanism involves structural damage of SA node or AV node and 
depresses nodal automaticity.  An abnormal  ectopic focus in the 
ventricle is other mechanism.  Prognosis is not affected by the 
 37 
presence of accelerated IVR.  There is no need for temporary 
pacing or antiarrhythmic drugs as it can result in clinically 
significant bradycardia or asystole hence an accelerated IVR should 
not be treated.   
Nonsustained ventricular tachycardia is defined as three or 
more consecutive ventricular ectopic beats with a rate more than 
100 bpm and should last less than 30 seconds. 
MECHANICAL COMPLICATIONS Of acute myocardial 
infarction are  
1) Ventricular free wall rupture  
2) Ventricular septal rupture  
3) Papillary muscle rupture with severe MR 
These complications can lead to cardiogenic shock. 
VENTRICULAR FREE WALL RUPTURE (VFWR) 
VFWR is most critical complication of AMI as the important 
cause of death after LV failure and also 15-30% of death in AMI is 
due to VFWR.
19-20
  VFWR can be associated with large transmural 
infarction and also antecedent infarct expansion.   
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The most serious complication of VFWR is acute 
haemopericardium and cardiac tamponade which can result in 
death. 
The incidence of VFWR 0.8-6.2%.   
The incidence has declined in recent years due effective 
blood pressure control measures, effective reperfusion therapy  
availability ACE inhibitors, beta-blockers, and reduced use of 
heparin.   
RISK FACTORS FOR VFWR ARE  
1) Age more than 70 years  
2) Female sex  
3) Newly diagnosed MI 
4) Q waves on ECG 
Therefore during acute phase of STEMI patients receiving 
fibrinolytic therapy later than 14 hours of onset of STEMI, in 
contrast patient who has history of angina pectoris in the past, 
multivessel coronary disease/chronic heart failure are less widely to 
develop VFWR due to presence of collaterals and ischaemic 
preconditioning.
21-22 
 39 
CLINICAL FEATURES   
It depends on acuity of onset, location and size of rupture. 
Patients present with severe chest pain, hypotension, 
haemodynamic Instability, asystole or death. 
In subacute course pateints present with hypotension, 
arrhythmias, syncope, shock or recurrent chest pain. 
THREE TYPES OF VFWR  
Type-1 Slit like tear usually associated with anterior infarcts 
and occurring with  24 hours. 
Type-2 At the border between infarcted and viable 
myocardium.  There is an erosion of infarcted 
myocardium. 
Type-3 Early aneurysm formation seen in old and severely 
expanded patients. 
DIAGNOSIS OF VFWR 
Early diagnosis and early treatment as necessary for survival.  
A high index of suspicion is essential. 
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Echo is the choice of diagnosis.  Diagnostic feature in echo 
are moderate to large pericardial effusion and impending 
pericardial tamponade. 
TREATMENT OF VFWR 
Prevention is by early reperfusion therapy or percutaneous 
coronary Intervention.  The best of choice is early surgical repair 
after  haemodynamic stability. 
IV fluids, ionotropic agents and pericardiocenters are 
emergency treatment. 
Surgical techniques include intraaortic balloon pump, 
infarctectomy, biologic glue patches with polythylene terephthalate 
polyester fiber, Teflon and use of pledgeted stures. 
The mortality rate is very high and it greatly depends patients 
preoperative hemodynamic status. 
VENTRICULAR SEPTAL RUPTURE 
This is rare but most life threatening complication of AMI.  
Inspite of appropriate medical and surgical therapy mortality rate is 
significantly high. 
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In olden ear i.e., prethrombolytic era incidence was 1-3%, 1 
at present, incidence is 0.2-0.34%
23-24. 
There is bimodal distribution with peak in first 24 hours and 
initial.  Second peak on days 3-5 and rarely after 2 weeks of AMI. 
Risk factors for ventricular rupture are  
1) Old age  
2) 65 years 
3) Female sex  
4) Poor septal collateral circulation  
5) Single vessel disease  
VSR can be classified into simple and complex. 
If the perforation is at same level on both sides of the septum 
with a direct  through and through communication as simple 
ventricular septal rupture. 
Complex septal rupture is one with extensive hemorrhage and 
irregular serpiginous traits. 
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Septal ruptures are mostly seen in anterior MI with occlusion 
of LAD artery.   
ECG changes in these include ST-segment elevation, Q waves 
in II, III, avF. 
CLINICAL FEATURES  
Chest pain, dyspnea, hypotension, LV failure, and shock. 
On examination, patient will have a holosystolic murmur.  
The murmur is best heard at lower left sternal border, other 
findings are palpable parasternal systolic thrill, S3 gallop. 
In patients who present with cardiogenic shock with VSR 
murmurs cannot be appreciated.  In contrast patients with acute MR 
may have soft systolic murmur in apex with no thrill. 
DIAGNOSIS OF VENTRAL SEPTAL RUPTURE 
Echocardiography, colour flow Doppler are the imaging 
modalities of choice uses of imaging technique as to assess 
ventricular function, to localize the site and size of septal rupture, 
to calculate RV systolic pressure and to quantify left to right shunt.  
Confirmation can be done by cardiac catheterization. 
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MANAGEMENT OF VSR 
Prompt diagnosis and immediate treatment is necessary.  
These steps in order has to be followed haemogynamic 
stabilization, angiography surgery.   
Supportive measures like nasal oxygen, ventilator support, 
diuretics, vasodilators , ionotropic agents should be used.  
Medical management is only temporary to stabilize patients 
before surgery.   
Current guidelines from the American College of Cardiology 
is emergency surgical repair irrespective of patients clinical 
condition.
25-28 
Surgical measures are hypothermic and cardiopulmonary 
bypass, removal of all friable margins of septum and necrotic area 
followed by reconstruction of ventricular walls and septum.  Latest 
technique which is being tried in some institution are percutaneous 
closure of septal rupture, datas about outcome of this method is still 
unavailable. 
Repetition of surgical repair is done in patients with 
pulmonary systemic traction more than 2 residual septal defect 
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following surgery is seen in 28% and the mortality rate is very 
high. 
Papillary muscle rupture with mitral regurgitation - One of the 
common complication of AMI is MR as a result of LV remodeling 
and it as an  
Independent risk factor for death
29-32
.  The usual period of 
occurrence of MR is 7-10 days following AMI where rupture can 
occur within 1-14 days.  When MR is mild/moderate it is detected 
in routine echocardiography following MI and rarely results in 
haemodynamic compromise. 
In contrast acute severe MR due to rupture of chordae 
tendinae/papillary muscles needs prompt surgical intervention as it 
can results in cardiogenic shock, haemodynamic instability and 
death. 
Incidence of MR in AMI patients is 1% and usually involves 
the posteromedial papillary muscle due to single blood supply as 
compared to anterolateral papillary muscle as it has double blood 
supply.
33-35 
Clinical features of mild to moderate MR are mostly 
asymptomatic, in acute severe MR patients present with dyspnea, 
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fatigue, shock.  On physical examination early to mid systolic 
murmur will be heard and is best heard at left lower sternal border.  
S3 and S4 gallop may be present. 
DIAGNOSIS  
High index of suspicion is needed in patients who present 
with cardiogenic shock, pulmonary edema or new systolic murmur 
at the apex.  Other imaging modalities are echocardiography, colour 
flow Doppler. 
MANAGEMENT  
To stabilize the patient haemodynamically, to find out exact 
mechanism of  MR are very essential for a good outcome.  
Pharmacological therapy includes  diuretics, ionotropic agents 
nitrates.  In haemodynamically unstable patients aortic balloon 
counterpulsation is the treatment of  choice. 
In case of papillary muscle rupture resulting in MR 
emergency surgical intervention is needed.  Either mitral valve 
repair, or mitral valve replacement has to be done. 
In patients presently intermittent MR as a result of recurrent 
ischaemia.   
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There is no need for emergency surgery.  Treatment for such 
patients is revascularization either by angioplasty or coronary 
artery bypass grafting. 
LEFT VENTRICULAR ANEURYSM  
         An abnormal outward bulging and deformation of a 
localized area of myocardium during both systole and diastole is 
known as left ventricular aneurysm. 
The incidence is 3-15% in AMI patients.  Risk factors are 
female sex, single vessel disease, occlusion of LAD and absence of 
any previous heart disease. 
The commonest location of LVA is aterolateral wall and 
usually occur with occlusion of LAD.  LVA is composed of fibrous 
scar. 
DIAGNOSIS  
Physical examination may reveal third of fourth heart sounds, 
enlarged cardiac silhouette in chest x-ray. 
ECG shows ST elevation, echo is 93% sensitive and 94% 
specific in diagnosis of LVA. 
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TREATMENT 
Conservative management with close follow up for small or 
clinically insignificant aneurysms 
Pharmacotherapy includes ACE inhibitors and 
anticoagulation for patients with left ventricular thrombus, and 
severe LV dysfunction. 
Indications for surgery are ventricular tachyarrhythmias 
refractory to medical treatments, severe heart failure, recurrent 
thromboembolism. 
Other miscellaneous complications of acute myocardial 
infarction are post  
MI syndrome (Dressler syndrome).  In this present era, 
incidence of post MI syndrome has reduced compared to olden days 
that is before the advent of reperfusion therapy.
36-37
  Dressler 
syndrome is considered to be an autoimmune process.  Clinical 
features are fever, chest pain.  Treatment measures are 
hospitalization and observation to look for development of cardiac 
tamponade.  Other measures are rest, steroids, NSAIDS.   
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PERICARDITIS 
Inflammation of the pericardial tissue which overlies 
infarcted myocardium is known as pericarditis.  Clinical 
manifestation are severe chest pain of pleuritic in nature.  ECG 
shows diffuse ST segment elevation
38
.  Treatment measures are 
aspirin, NSAIDS. 
Left ventricular mural thrombus - is a complication usually 
associated with anterior infarcts.  Incidence ranges from 20-40%.  
Patients with LVMT are  at high risk of developing systemic 
embolization.  
Anticoagulation therapy is the treatment of choice.  LVMT 
formation is affected by LV regional wall ischaemia, inflammation 
etc. Echocardiography is the imaging modality and choice.  
Pharmaceutical therapy includes Heparin followed by warfarin.  
MAGNESIUM  
Magnesium is a cofactor for many enzymatic reactions and 
plays a very important role in many physiological functions.  
Though magnesium is one of the important elements it is most 
neglected one. Hypomagnesemia is more important than 
hypermagnesmia.   
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Serum magnesium measurement is the most easy and 
affordable method although it does not reflect total content of 
magnesium in the body.  In spite of having similar charge and 
chemical reactivity as calcium.  It has antagonistic behavior.  Total 
magnesium content in the body is 20 mmol/kg of fat free tissue
39
.  
Average magnesium in an adult of about 70 kg will be 1000 to 1120 
mmol.  Bone has 99% of the total magnesium remaining is present 
in the skeletal muscles.  Hence bone and skeletal muscles provides 
reservoir of exchangeable magnesium to maintain physiological 
extracellular magnesium levels.   
Intracellular magnesium is about 5-20 mmol/l and 1-5% is 
ionized and the rest is bound to proteins and ATP.  1% of the total 
magnesium is in the extracellular compartment, mainly in serum 
and RBCs.   
Serum magnesium can be free or ionized and bound to anions 
like phosphate, bicarbonate, sulfate, citrate or proteins.  Ionized 
magnesium has maximum biological activity.  
Magnesium is usually intracellular and it acts as a cofactor 
for more than 300 enzymatic reactions mainly ATP synthesizing 
reactions.  Magnesium plays a role in the following reactions - 
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glucose utilization, synthesis of proteins, fat, coenzymes and 
nucleic acid.  Hence variation in magnesium levels can affect all 
these reactions.  As a result magnesium plays a role in normal 
neurological function, muscle contraction and relaxation, 
neurotransmitter release, to regulate vascular tone, to maintain 
heart rate and helps in bone formation.
41
   
REQUIREMENT OF MAGNESIUM 
Humans have to include magnesium in diet regularly to 
prevent magnesium deficiency.  Recommendation of Institute of 
Medicine is 310-360 mg for adult woman and 400-420 mg per day 
for adult men and 355 mg in pregnancy and lactation.  Drinking 
water contains 10% of our daily magnesium intake and it acts a 
major magnesium source for humans
43
.   
Other source of magnesium are nuts, unprocessed cereals and 
seeds, fruits, legumes and meat.  Dairy products are low in 
magnesium content. 
MAGNESIUM ABSORPTION AND EXCRETION        
Magnesium concentration is maintained by bone, kidneys and 
intestine.   
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Magnesium is mainly absorbed in small intestine 24-76% of 
magnesium is absorbed in the gut and the rest is eliminated in 
faeces.  Kidneys also play a important role in maintaining 
magnesium homeostasis.  Glomeruli filters 2400 mg of magnesium 
present in the plasma.  95% is reabsorbed immediately and 
remaining 3-5% was excreted via urine.   
Major reabsorption site for magnesium is thick ascending 
limb of Loop of Henle. 
MAGNESIUM STATUS ASSESSMENT   
There are three methods, extracellular fluid has only 1% of 
total body magnesium.  First method is serum magnesium 
estimation.  As only 0.3% of total body magnesium is found in 
serum.  It is not a good indicator of magnesium levels.  Haemolysis 
has to be avoided as magnesium content is high in RBCs. 
 Second method is 24 hours excretion in urine - the test is 
little cumbersome and not much reliable.  It requires 24 hours and 
is useful to assess difference between magnesium wasting by 
kidneys and medicines.   
Renal wasting is indicated by high urinary excretion and low 
values indicate decreased intake or absorption.
43 
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Third method is loading test/magnesium retention test - may 
serve for identification of patients with hypomagnesmic and 
normomagnesemic magnesium deficiencies.  Retention of 
magnesium following acute oral or IV administration helps in 
assessing chronic loss.  Magnesium is retained in bone hence 
decrease in bone content will cause higher retention in this test.  It 
is a sensitive index of magnesium deficiency.  Recent method is 
isotropic analysis of magnesium.   
PATHOPHYSIOLOGY  
Serum magnesium estimation and collection of 24 hours urine 
are the methods to detect hypomagnesemia.  Normal magnesium 
concentration is 1.5 mg/dl.  Hospitalized patients are at higher risk 
of developing hypomagnesemia.   
Medications causing hypomagnesemia are Cisplatin,  
Digoxin, aminoglycoside, Lasix. Patients with low 
magnesium levels have poor prognosis, requires more days for 
weaning from ventilators and high mortality rate. Causes for 
hypomagnesemia are poor intake, GI loss, diarrhea, malabsorption.  
Other causes include RTA, DM, hyperthyroidism, hypercalcemia 
and diuretics use.  Chronic hypomagnesemia is difficult to diagnose 
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as it has only very little negative equilibrium.  Causes are 
myocardial infarction, atherosclerosis, hypertension, premenstrual 
syndromes, kidney stones and psychiatric disorders. 
CLINICAL FEATURES 
They are nonspecific.  Features are muscle fasciculation, 
tremors, depression, agitation, arrhythmias and other electrolyte 
abnormalities like hypokalaemia.  Other features are loss of 
appetite, fatigue, nausea, vomiting and weakness.  As magnesium 
level decreases features like numbness, tingling sensation, cramps, 
involuntary muscle contractions and seizures can occur.   
Hypermagnesemia - Here again kidneys plan important role.  
In chronic kidney disease the compensatory mechanism will start to 
fail and results in high magnesium levels.  Causes include excessive 
intake, antacids or laxative use.  Incidence varies from 5.7-8%.   
Clinical Features - slight elevation may cause hypotension, 
nausea, vomiting, cutaneous flushing, bradycardia, QT prolongation 
ECG and absence of tendon reflexes. 
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TREATMENT OF HYPO AND HYPERMAGNESEMIA 
In stable patients with hypomagnesemia oral administration is 
the choice.  IV administration of magnesium is used in acute 
conditions like ventricular arrhythmias.  Treatment of  
hypermagnesemia is to discontinue the offending drug and severe 
hypermagnesemia is an indication for haemodialysis .   
USES OF MAGNESIUM 
Magnesium has an important role in IHD pathogenesis,and 
others like CAD, coronary artery spasm, atherosclerosis, coronary 
artery thrombosis, hypertension, chronic heart failure and 
arrhythmias.   
INDICATIONS FOR MAGNESIUM SUPPLEMENTATION 
1) Previous history of heart attack  
2) Risk of developing ventricular arrhythmia  
3) Systemic hypertension - has direct relationship between low 
magnesium levels and high BP. 
4) CCF patients 
5) Diabetes  
6) Dyslipidemia 
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7) Ischaemic heart disease  
8) Coronary artery spasm/thrombosis  
9) Cardiac myopathy  
10) Digoxin related arrhythmias 
11) Torsedes de pointes 
12) On patients with diuretic supplementation 
13) Normal healthy patients without any coronary renal disorder 
or hypertension can be given magnesium supplementation to 
get sufficient magnesium insurance. 
The best thing is to have diet rich in fresh fruits and 
vegetables with nutrient supplementation in order to maintain good 
magnesium stores and protect ourselves from cardiac conditions.  
AIMS AND OBJECTIVES 
1) To know the relation between level of serum magnesium and 
incidence of arrhythmias in patients with acute myocardial 
infarction who are presenting within 12 hours of onset of 
symptoms at Govt kilpauk Medical College & Hospital.  
2) To assess how the variables like   
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a. Diabetes 
b. Chronic kidney disease 
c. Dyslipidemia 
d. Low ejection fraction affects magnesium levels in 
myocardial infarction patients.  
METHODS AND MATERIALS: 
Study Group : All cases of acute myocardial infarction      
admitted in KMCH satisfying the case 
definition   
Study design : Cohort study 
Duration of study : 6 months 
Conflict of interest : Nil. 
Inclusion criteria : 
Those patients presenting to hospital within 12 hours of onset 
of symptoms of angina. 
Patients were considered to have acute myocardial infarction 
if they have any of the following criteria: 
1) ECG changes of acute myocardial infarction. 
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2) Rise of cardiac enzymes. 
Exclusion criteria : 
Patients with hypokalemia.  
METHODOLOGY 
 
 The data of each patient was collected in the specific 
proforma which includes the name, age, sex.  
 Each selected patient was subjected to detailed history and 
thorough physical examination.   
 ECG was taken immediately after admission and everyday 
during the hospital stay.  
 Investigations like Urea, Creatinine, Sodium, Potassium was 
done on the day of admission. 
 Fasting lipid profile was done the next day.    
 Serum Magnesium levels were assessed within 24 hours of 
admission and on the day of discharge/fifth day.  
 Fasting blood sugar status was assessed everyday in diabetics.  
 2D Echocardiography was also done during the in-patient stay. 
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METHOD OF SERUM MAGNESIUM ESTIMATION 
Blood samples of all the fifty patients selected was collected 
immediately after admission and serum was separated and 
magnesium analysis was done using  magnesium kit 
(CALMAGITE METHOD) and on fifth day.  
PRINCIPLE 
This method helps to determine magnesium in serum, urine 
and CSF. 
Magnesium combines with calmagite in an alkaline medium 
to form a red  coloured complex.  Any interference by calcium and 
proteins is eliminated by adding specific chelating agents or 
detergents.  The intensity of red colour formed is directly 
proportional to the level of magnesium contained in the sample.  
REFERENCE VALUES 
Serum – (children 1.5-2 mEq/l, adult 1.5-2.5 mEq) 
CSF- 2-3 mEq/l  
Urine - 6-8 mEq/24 hours 
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CONTENTS IN THE KIT 
Contents 25 ml 75 ml 
L1: Buffer reagent 12.5 ml 37.5 ml 
L2: Colour reagent 12.5 ml 37.5 ml 
S: Magnesium standard 2 ml 2 ml (2 mEq/l) 
The contents are stable at 2-8 degree C and the reagents are 
ready to use.  Magnesium in serum or plasma is stable for seven 
days at 2-8 degree C. 
PROCEDURE  
Wavelength or filter: 510 mm/green. 
Temperature:  Room temperature  
Light path:  1 cm  
Pipette into clean dry test tube labeled as blank (B), standard 
(S), and test (T) 
Addition Sequence B (ml) S(ml) T (ml) 
Buffer reagent (L1) 0.5 0.5 0.5 
Colour reagent (L2) 0.5 0.5 0.5 
Distilled water 0.5 0.5 0.5 
Magnesium standard (S) 0.01 – – 
Sample 0.01 – – 
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The samples are mixed well and incubated at room 
temperature for 5 minutes and the measurement of absorbance of 
the standard and test sample against the blank was measured within 
30 minutes. 
CALCULATIONS 
Magnesium in mEq  =  Abs.T/Abs.S x 2 
This procedure is linear up to 10 mEq/l. 
Note:  All precautions were taken to clean the test tubes used 
with 1% Hcl and were deionized before use.  All the chelating 
agents and EDTA were removed completely before using the test 
tubes. 
STATISTICAL ANALYSIS 
The present chapter is based on the analysis of data and 
interpretation and discussion ofresults. However valid, reliable and 
adequate the data may be, it does not serve and purposeunless the 
data is carefully processed, systematically classified, scientifically 
analyzed,properly interpreted and rationally concluded.  
After the data had been collected, it was processed & 
tabulated directly in to SPSS 17.0 software. SPSS version 17.0 
statistical software was used and the results obtained thereby have 
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been analyzed and interpreted. These have been done on Age, 
gender, SHT, DM, CAD, Smoker, Alcoholic, Cholesterol, TGL, 
Arrhythmia Days, Arrhythmia Type,  AWMI, IWMI, LWMI, 
ANGI, Magnesium level at day one and day five. 
The purpose of the study isto find out the tendency of each 
parameter and also intends to find out the differences in the 
magnesium level in repeated observations, association of the 
arrhythmia with demographic, risk factor and Diagnosis variables 
namely, gender, age, SHT, DM, CAD, Smoking, Alcoholic, AWMI, 
IWMI, LWMI and Angi. 
The following statistical techniques were used for analyzing 
the data 
1) Descriptive statistics – Frequency, Means, Standard 
Deviation and Percentages. 
2) Multiple responses tabulation was made to capture the 
frequency and combination of more than one diagnosis in the 
patients. 
3) Paired t statistics was used to find out difference between the 
level of magnesium in the Day 1 Mg mEq/L and Day 5 Mg 
mEq/L among the patients. 
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4) Chi- Square test was used to find association between 
Presence of Arrhythmia and demographic profile; similarly 
with the Risk Factors and Diagnosis. 
5) Independent t Statistics was performed to find the 
significance between presence and absence of Arrhythmia in 
several factors. 
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RESULTS 
Descriptive Statistics 
Parameter N Mean SD (Max - Min) 
Age 50 54.4 12.4 (80 - 25) 
Cholesterol 50 194.5 26.8 (262 - 128) 
TGL 50 142.5 24.8 (199 - 78) 
Arrhythmia Days 32 1.8 0.9 (1 - 4) 
 
Of the 50 patients selected the age deviation was from 
minimum of 25 years and a maximum of 80 years with a mean of 
54.4 and a standard deviation of 12.4. 
32 patients out of 50 had arrhythmias in the course of hospital 
stay from day 1 to day 4 with a mean of 1.8 days with a standard 
deviation of 0.9.  Cholesterol and triglyceride levels were estimated 
which range from maximum to minimum of 262 to 128 and 199 to 
78 respectively. 
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Descriptive Statistics 
Parameter n % 
Gender 50  
Male 42 84.0% 
Female 8 16.0% 
 
Total people under the study were 50 of which 42 are male 
(84%) and 8 were female (16%). 
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Descriptive Statistics 
Parameter n % 
SHT 50  
NO 20 40.0% 
YES 30 60.0% 
 
30 (60%) out of 50 patients had the risk of hypertension and 
20 (40%) were not a known hypertensive. 
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Descriptive Statistics 
Parameter n % 
DM 50  
NO 19 38.0% 
YES 31 62.0% 
 
31 (62%) out of 50 patients were known diabetic, 19 (38%) 
were nondiabetics in the study and the distribution is shown in the 
diagram above. 
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Descriptive Statistics 
Parameter n % 
CAD 50  
NO 36 72.0% 
YES 14 28.0% 
 
36 (72%) out of 50 patients were not a known CAD and 14 
(28%) were known CAD patients and the diagrammatic 
representation as shown above.  
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Descriptive Statistics 
Parameter n % 
Smoker 50  
NO 21 42.0% 
YES 29 58.0% 
 
29 (58%) people out of 50 were smokers when compared to 
21 (42%) people were nonsmokers. 
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Descriptive Statistics 
Parameter n % 
Alcoholic 50  
NO 36 72.0% 
YES 14 28.0% 
 
14 (28%) out of 50 patients were alcoholic and 36 (72%) 
were not a known alcoholic which is illustrated in the diagram 
above. 
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 76 
Descriptive Statistics 
Parameter n % 
ARRHYTHYMIA 50  
NO 18 36.0% 
YES 32 64.0% 
 
In this study 32 (64%) out of 50 MI patients developed 
arrhythmias during the stay in the hospital and 18 (36%) maintain 
normal sinus rhythm (had no arrhythmias) during the course of stay 
in the hospital. 
 77 
 
 78 
Descriptive Statistics 
Parameter n % 
DIAGNOSIS   
AWMI 50  
NO 27 54.0% 
YES 23 46.0% 
IWMI 50  
NO 28 56.0% 
YES 22 44.0% 
LWMI 50  
NO 47 94.0% 
YES 3 6.0% 
ANGI 50  
NO 48 96.0% 
YES 2 4.0% 
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Multiple Responses on Diagnosis 
Diagnosis n % % of Cases 
AWMI 23 19.3% 46% 
IWMI 22 18.5% 44% 
LWMI 3 2.5% 6% 
ANGI 2 1.7% 4% 
Total 119 100.0% 238.0% 
 
23 (46%) out of 50 patients had anterior wall MI. 
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AWMI 
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IWMI 
 
22 (44%) were inferior wall MI patients. 
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LWMI 
 
3 (6%) patients had lateral wall MI. 
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UNSTABLE ANGINA 
 
2 (4%) patients in the study suffered from unstable angina.  The above diagrams illustrate the type of MI in 
the 50 patients under study. 
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Descriptive Statistics 
Parameter n % 
ARRHYTHYMIA TYPE 32  
1st Deg. Heart Block 3 9.4% 
AF 5 15.6% 
CHB 2 6.3% 
LBBB 2 6.3% 
PAC 2 6.3% 
PBBB 2 6.3% 
Sinus Brady Cardia 3 9.4% 
SVT 3 9.4% 
Torsedes de Pointes 1 3.1% 
Ventricular Bigemini 1 3.1% 
VPC 8 25.0% 
Of 32 patients who developed arrhythmias 3 (9.4%) had inferior 
wall MI, 5 patients (15.6%) developed atrial fibrillation, 2 (6.3%) 
developed complete heart block, 2 (6.3%) had LBBB, 2 (6.3%) had 
PAC, 2 (6.3%) had RBBB, 3 (9.4%) developed sinus bradycardia, 3 
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(9.4%) had SVT, 1  (3.1%) developed torsedes de pointes, 1 (3.1%) 
developed ventricular bigemini and 8 (25%) had VPC.   
This is the distribution of type of arrhythmias in the study 
group. This shows that VPCs are most common among patients who 
develop MI. 
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Presence of Arrhythmia Vs. Risk Factors 
 
Arrhythmia 
Total 
Chi-
square 
Statistics 
p - 
Value 
No Yes 
SHT NO 16 (32%) 4 (8%) 20 (40%) 
28.009 0.000 
YES 2 (4%) 28 (56%) 30 (60%) 
DM NO 15 (30%) 4 (8%) 19 (38%) 
24.533 0.000 
YES 3 (6%) 28 (56%) 31 (62%) 
CAD NO 12 (24%) 24 (48%) 36 (72%) 
0.397 0.529 
YES 6 (12%) 8 (16%) 14 (28%) 
SMOKER NO 9 (18%) 12 (24%) 21 (42%) 
0.739 0.390 
YES 9 (18%) 20 (40%) 29 (58%) 
Alcoholic NO 16 (32%) 20 (40%) 36 (72%) 
3.979 0.046 
YES 2 (4%) 12 (24%) 14 (28%) 
Total 18 (36%) 32 (64%) 50 (100%)     
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Of the 30 (60%) known systemic hypertensive patients 28 
(56%)  developed arrhythmias and 2 (4%) do not have arrhythmia.  
Using the Chi-square statistics T value is 0.000. 
28 (56%) out of 31 (62%) diabetics had arrhythmias and 3 
(6%) patients did not have arrhythmias and 4 (8%) out of 19 (38%) 
nondiabetics had arrhythmias.  Here again using the Chi-square test 
P value is 0.000. 
Of the known CAD patients 14 (28%), 8 (16%) had 
arrhythmias and among 36 (72%) non CAD patients 24 (48%) had 
arrhythmias. 
Among 29 (58%) smokers, 20 (40%) had arrhythmias.  
Out of 14 (28%) alcoholics, 12 (24%) had arrhythmias.  
This tabular column and the diagrams illustrate that risk 
factors such as smoking, alcohol, hypertension, diabetes increases 
the risk of arrhythmias with P value being highly significant.  
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Presence of Arrhythmia Vs. Diagnosis 
 
Arrhythmia 
Total 
Chi-
square 
Statistics 
p - 
Value 
No Yes 
Dia_AWMI NO 9 (18%) 18 (36%) 27 (54%) 
0.181 0.670 
YES 9 (18%) 14 (28%) 23 (46%) 
Dia_IWMI NO 13 (26%) 15 (30%) 28 (56%) 
3.004 0.083 
YES 5 (10%) 17 (34%) 22 (44%) 
Dia_LWMI NO 16 (32%) 31 (62%) 47 (94%) 
1.303 0.254 
YES 2 (4%) 1 (2%) 3 (6%) 
Dia_angi NO 16 (32%) 32 (64%) 48 (96%) 
3.704 0.054 
YES 2 (4%) 0 (0%) 2 (4%) 
Total 18 (36%) 32 (64%) 50 (100%)     
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Presence of Arrhythmia Vs. Demographics 
 
Arrhythmia 
Total 
Chi-
square 
Statistics 
p - 
Value 
n (%) n (%) 
No Yes 
GENDER 
Female 2 (4%) 6 (12%) 8 (16%) 
0.500 0.479 
Male 16 (32%) 26 (52%) 42 (84%) 
Age 
Up to 
30 
1 (2%) 0 (0%) 1 (2%) 
6.206 0.287 
31 - 40 3 (6%) 5 (10%) 8 (16%) 
41 - 50 6 (12%) 4 (8%) 10 (20%) 
51 - 60 5 (10%) 12 (24%) 17 (34%) 
61 - 70 1 (2%) 6 (12%) 7 (14%) 
> 70 2 (4%) 5 (10%) 7 (14%) 
Total 18 (36%) 32 (64%) 50 (100)     
There is not much significant difference in the incidence of 
arrhythmias among males and females and among different age groups. 
There is no significant variation in the incidence of 
arrhythmias among the different types of MI. 
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Paired Sample t Statistics 
Pair N Mean SD Correlation Mean Diff. t - Statistics P - Value 
Day 1 
Mg 
mEq/L   
Vs.     
Day 5 
Mg 
mEq/L 
49 
 1 
1.537 0.431 
0.791** -0.355 -8.567** 0.000 
1.892 0.462 
** significant at 1% level 
Incidence of arrhythmia in day 1 and day 5 is significantly high. 
 
Out of 50 patients 32 of them had arrhythmias and using 
independent T statistics P value is highly significant.  There is not much 
significant difference in the development of arrhythmia in relation to day 
following MI.  
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ARRHYTHMIA VS. MAGNESIUM DAY 1 AND DAY 5 
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Independent t Statistics between presence and absence of 
Arrhythmia 
Arrhythmia N Mean SD Mean Diff. t Statistics p Value 
CHOLESTEROL 
No 18 194.9 27.7 
0.639 0.080 0.936 
Yes 32 194.3 26.6 
TGL 
No 18 145.7 28.4 
4.979 0.677 0.502 
Yes 32 140.7 22.9 
Day 1 Mg m Eq/L 
No 18 2.0 0.3 
0.743 10.665** 0.000 
Yes 32 1.3 0.2 
Day 5 Mg m Eq/L 
No 18 2.3 0.3 
0.645 6.366** 0.000 
Yes 32 1.7 0.4 
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Arrhythmia N Mean SD Mean Diff. t Statistics p Value 
Mg m Eq/L (Diff. from Day 5 to Day 1) 
No 18 0.3 0.143 
-0.096 -1.118 0.269 
Yes 31 0.4 0.345 
** significant at 1% level 
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MAGNESIUM COMPARISON   
 
Serum magnesium levels were low on the day of admission 
and progressively increased after that. 
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DISCUSSION 
Magnesium has become a premier cardiovascular cation in the 
present decade.   
Magnesium plays an important role in the pathogenesis of 
acute myocardial  
Infarction as well as its complications.  Magnesium is needed 
for activation of  ATP which helps to maintain the sodium 
potassium pump and blocks calcium which has been implicated to 
the cause of arrhythmias in myocardial infarction patients.  
In this study group of 50 patients, 42 were male and 8 were 
female.  Of the 50 patients 30 of them were known hypertensives 
and 20 were nonhypertensives.  The maximum incidence of 
myocardial infarction was between 40 and 50 years of age.   
The serum magnesium level was calculated immediately on 
the day of admission for all the 50 patients and the mean serum 
magnesium level on day 1 was 1.3 for patients with arrhythmia and 
2 for patients without arrhythmia. 
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Mean serum magnesium level on day 5 was 1.7 for patients 
who developed arrhythmia and 2.3 for patients who had no 
arrhythmia during hospital stay. 
Dim truck
51
 in his study of 67 patients with ischaemic heart 
disease showed a reduction in serum magnesium levels in the first 
three days of MI and the levels became normal by 15-25 days after 
MI. 
In this present study serum magnesium levels of patients who 
developed arrhythmia are significantly low with a P value of 0.000.  
There was an increase in serum magnesium levels from day 1 to 
day 5 in both with and without arrhythmias.   
Ventricular arrhythmias are more common than atrial 
arrhythmias. 
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CONCLUSION 
This study was done in 50 patients who were being admitted 
to the cardiology department of Kilpauk Medical College during the 
period of April 2014 to September 2014.  There were 42 males and 
8 females included in the study.  The most common risk factor 
found was hypertension, diabetes, smoking and alcohol.  
The mean serum magnesium level on day 1 for patients with 
arrhythmia was 1.3 and 2 for patients without arrhythmia  and the P 
value was highly significant with value of less than 0.000.  On day 
5 the mean serum magnesium levels with and without arrhythmias 
were 1.7 and 2.3 respectively again with a highly significant P 
value of 0.000. 
The percentage of people who developed arrhythmia in the 
study was 64%.  60% were hypertensives and 62% were diabetics.  
The distribution of type of MI were as follows  
19.3% of them had AWMI, 18.5% had IWMI, 2.5% had 
LWMI and 1.7% had unstable angina.  There was no significant 
difference in the incidence of arrhythmias among different types of MI. 
Of the 60% of hypertensives 56% of them developed 
arrhythmias and among 62% of the diabetics 56% of them had 
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arrhythmias.  The P value calculated by Chi-square test is 0.000.  
Of 28% of the known CADs 16% had arrhythmias and among 72% 
of the non CADs 48% had arrhythmias.  There is no difference and 
the incidence of arrhythmias in CADs and non CADs. 
With regard to smoking and alcohol there is significant 
difference in the incidence of arrhythmias. 
Hence to conclude the incidence of arrhythmias in acute 
myocardial infarction is more in patients with low magnesium 
levels.  The normal value being 1.5 mg/dl to 2.5 mg/dl.  Diabetes, 
hypertension, smoking and alcohol are the major risk factors.  
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CLINICAL SIGNIFICANCE 
Incidence of arrhythmia is about 90% in myocardial 
infarction patients and hence treating them with Magnesium 
Sulphate on the first day will prevent arrhythmias in the future. 
Oral Magnesium supplementation following Myocardial Infarction 
can be beneficial.  
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PROFORMA 
 
NAME:      UNIT NO.:                
AGE/SEX:                               I.P.NO.: 
OCCUPATION:                                      DATE OF ADMISSION:  
ADDRESS:             DATE OF DISCHARGE: 
 
 
CONTACT NO: 
COMPLAINTS: 
 
 
 
Past history: Diabetes mellitus/systemic hypertension 
 
 
 
GENERAL EXAMINATION 
VITALS: 
BP:                 PR:                 RR: 
SYSTEM EXAMINATION: 
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INVESTIGATIONS:  
Renal Profile 
Random sugar Urea Creatinine 
   
 
Sr. Sodium Sr. Potassium 
  
 
Sr. Magnesium within 24 hours of 
admission 
Sr. Magnesium on Day of 
Discharge 
  
Fasting Blood Sugar (In Diabetics) 
Day 1 Day 2 Day 3 Day 4 Day 5 
     
Fasting Lipid Profile 
Total Cholesterol Triglycerides 
  
ECG In All Leads 
DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 
     
2D ECHOCARDIOGRAPHY:    
 
Signature of Investigator                                 Signature of Guide 
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ABBREVIATIONS USED 
CCF   Congestive cardiac failure 
AMI   Acute myocardial infarction 
CAD  Coronary artery disease 
IHD  Ischaemic heart disease 
 CABG  Coronary artery bypass grafting 
LBBB  Left bundle branch block 
PCI  Percutaneous coronary intervention 
NSTEMI  Non ST elevation Myocardial Infarction 
AWMI  Anterior wall myocardial infarction 
IWMI  Inferior wall myocardial infarction 
LWMI   Lateral wall myocardial infarction 
LVH  Left ventricular hypertrophy 
HOCM  hypertrophic  obstructive cardiomyopathy 
DM  Diabetes mellitus 
CPR  cardio pulmonary rescucitation 
AF  Atrial fibrillation 
LAFB  Left anterior fascicular block 
SVT  Supra ventricular tachycardia 
LAD  Left anterior descending 
 
Mr. L. Mansoor 55 Male 1409053 1/4/14 5/4/14 No Yes No Yes No 236 172 No arrhythmia
Mr. Ammavasai 65 Male 1408814 2/4/14 6/4/14 Yes Yes No Yes Yes 240 152 3
Mr. Dass 46 Male 1409150 2/4/14 6/4/14 Yes No Yes No No 200 156 1
Mr. Subramani 73 Male 1409319 3/4/14 7/4/14 Yes Yes No No No 222 148 1
Mr. Sundaram 73 Male 1409568 4/4/14 9/4/14 No No No Yes No 206 152 No arrhythmia
Mr. Ravikumar 65 Male 1409553 5/4/14 10/04/14 Yes No No Yes No 220 158 No arrhythmia
Mr. Thillai Ganesh 51 Male 1409611 5/4/14 10/4/14 Yes Yes Yes Yes No 238 162 3
Mr. Kumar 48 Male 1409658 6/4/14 10/4/14 No No No Yes No 200 148 No arrhythmia
Mrs. Geetha 38 Female 1409622 6/4/14 10/4/14 Yes Yes No No No 186 150 2
Mr. Kantha Rao 44 Male 1409736 7/4/14 11/4/14 Yes Yes No Yes No 210 154 2
Mr. Selvam 46 Male 1410066 9/4/14 14/4/14 No No No No No 172 150 No arrhythmia
Mr. Munusamy 60 Male 1410274 11/4/14 15/4/14 Yes Yes Yes Yes No 200 154 1
Mr. Kaliappan 40 Male 1410319 11/4/14 16/4/14 Yes Yes Yes Yes No 216 160 1
Mr. Manimaran 25 Male 1410739 15/4/14 19/4/14 No No No No No 182 149 No arrhythmia
Mr. Ramamurthy 59 Male 1410974 18/4/14 23/4/14 Yes Yes No Yes Yes 204 154 1
Mrs. Chokammal 75 Female 1411328 21/4/14 25/4/14 Yes Yes No No No 216 150 1
Mr. Murugan 75 Male 1411480 23/4/14 27/4/14 No No Yes Yes No 182 146 No arrhythmia
Mrs. Meenakshi 60 Female 1411223 21/4/14 26/4/14 Yes No No No No 202 158 2
Mrs. Kumari 60 Female 1411660 24/4/14 29/4/14 No Yes Yes No No 178 152 No arrhythmia
Mr. Velayutham 63 Male 1411763 25/4/14 29/4/14 No Yes No Yes No 190 138 2
Mr. Rajasekar 40 Male 1411427 27/4/14 1/5/14 Yes Yes No Yes Yes 175 150 1
Mr. Parthasarthy 57 Male 14123114 30/4/14 1/5/14 Yes Yes Yes Yes No 208 179 1
Mr. Sowrimuthu 56 Male 14112464 1/5/14 4/5/14 No No Yes No No 222 180 No arrhythmia
Mr. Kareem 54 Male 1412881 5/5/14 9/5/14 Yes Yes No Yes No 181 139 1
Mr. Krishnamurthy 56 Male 1412580 2/5/14 7/5/14 Yes Yes No Yes Yes 214 156 1
Mr. Selvaraj 65 Male 141276 4/5/14 7/5/14 Yes No Yes Yes No 190 138 4
Mr. Ravindran 54 Male 1413058 7/5/14 12/5/14 No No Yes Yes Yes 208 154 No arrhythmia
Mrs. Malathy 40 Female 1413783 8/5/14 13/5/14 Yes Yes No No No 209 157 2
Mrs. Gunasundari 40 Female 1413488 8/5/14 14/5/14 Yes Yes No No No 199 155 No arrhythmia
Mr.Ponnambala 47 Male 1413220 8/5/14 12/05/14 No Yes No No No 200 138 3
Mr. Suman 46 Male 1413567 10/5/14 14/5/14 Yes Yes No Yes Yes 209 162 2
Mr. Vembu 65 Male 1413104 7/5/14 13/5/14 Yes Yes No Yes Yes 168 132 1
Mr. Irudayaraj 38 Male 1414252 16/05/14 21/05/14 No No Yes Yes No 201 199 No arrhythmia
Mr. Shanmugam 36 Male 1413980 13/05/14 19/05/14 Yes No Yes No No 208 150 3
DOD SHT DM CAD Smoker Alcoholic CholesterolName Age Sex IP Number DOA TGL Day of arrhythmia 
DOD SHT DM CAD Smoker Alcoholic CholesterolName Age Sex IP Number DOA TGL Day of arrhythmia 
Mr. Murali 50 Male 1414414 17/05/14 22/05/14 No No No No No 178 100 No arrhythmia
Mr. Govindan 75 Male 1414307 17/05/14 24/05/14 Yes Yes No Yes Yes 128 88 3
Mr. Prakash 35 Male 1414962 22/05/14 28/05/14 No No No Yes No 172 110 No arrhythmia
Mr. Chinnaraj 56 Male 1414960 22/05/14 26/05/14 Yes Yes No Yes Yes 138 78 1
Mr. Srinivasan 54 Male 1415272 25/05/14 29/05/14 Yes Yes No No No 205 100 1
Mr. Hasi Bul 54 Male 1415477 26/05/14 29/05/14 No Yes No Yes Yes 190 132 2
Mr. Balmurugan 43 Male 1415880 28/05/14 31/05/14 No No No No No 168 115 No arrhythmia
Mr. Vadivel 65 M ale 1416100 29/05/14 4/6/14 Yes Yes No Yes No 138 133 1
Mr. Jony Basha 50 Male 1417519 13/06/14 18/06/14 No No No No No 152 90 No arrhythmia
Mr. Anandhan 51 Male 1418575 21/06/14 24/06/14 No Yes No No No 187 130 2
Mrs. Saraswathy 57 Female 1419007 25/06/14 30/06/14 Yes Yes No No Yes 221 159 3
Mr. Pichai 75 Male 1419118 3/7/14 7/7/14 Yes Yes Yes Yes Yes 165 99 1
Mr. Selvaraj 62 Male 1419120 4/7/14 9/7/14 Yes Yes No Yes Yes 191 121 1
Mrs. Pattamal 80 Female 1419225 5/7/14 10/07/14 Yes Yes No No No 167 125 2
Mr. Joseph 42 Male 1419230 8/7/14 13/07/14 No No No No No 170 122 No arrhythmia
Mr. Balaji 55 Male 1419233 11/7/13 16/07/14 No No Yes Yes Yes 262 170 No arrhythmia
Day 1 Day 5
DM type 2 SHT/EXT. AWMI 2 2.5 RWMA+, EF 48%, Mod LV dysfunction No         -
DM/SHT/IWMI 1.4 1.8 No RWMA, normal LV function, EF 60% Yes VPC
CAD/IWMI 1 1.5 RWMA+, EF 38% Yes 1st degree HB
DM/SHT/AWMI 1.2 1.8 No RWMA, normal LV function Yes S. Bradycardia
DM/IWMI 2 2.5 RWMA+, EF 40% No         -
DM/SHT/AWMI/ 2.5 2.7 Mild LVH+, mild hypokinesia+, EF 48% No         -
SHT/CAD/IWMI 1.4 1.6 LVH+, EF 52% Yes VPC
AWMI 2 2.2 No RWMA, normal LV sys function No         -
DM/IWMI 1.2 1.7 No RWMA, normal LV sys function Yes RBBB
DM/SHT/Ext. AWMI 1.3 1.9 RWMA+, EF 40% Yes VPC
DM/SHT/Ext. AWMI 2 2.3 LVH+, No RWMA, EF 70% No       -
CAD/Ext./ AWMI 1.1 1.5 Tachycardia during study, No RWMA Yes AF
SHT/CAD/IWMI 1.2 1.8 Severe RWMA+ EF 30%, Severe LV Yes 1st degree heart block
AWMI 2.4 2.5 No RWMA, normal systolic function No          -
DM/SHT/IWMI 1 1.5 RA/RV dilated, EF 50% Yes SVT
DM/SHT/AWMI 1.4 1.8 No RWMA, normal LV function Yes AF
DM/SHT/CAD/LWMI 2.4 2.7 No RWMA, normal LV function No             -
SHT/IWMI 1.5 1.9 No RWMA, normal LV function Yes Ventricular bigemini
DM/SHT/CAD/AWMI 1.8 2.3 No RWMA, normal LV function No                 -
DM/IWMI 1.1 1.5 RWMA+/EF 48%/mild LV dysfunction Yes 1st degree heart block
Ac. IWMI 1.4 2 No RWMA, normal LV function Yes PAC
SHT/CAD/IWMI 1.2 1.6 RWMA+, EF 37%, Yes LBBB
CAD/Ac. IWMI 1.8 2.2 No RWMA, normal LV function No                -
DM/IWMI 1 1.5 RWMA+, EF 50%, mild LV dysfunction Yes AF
DM/SHT/IWMI 1.3 1.8 No RWMA, normal LV function Yes VPC
IWMI 1.1 - No RWMA Yes CHB
DM/SHT/CAD/LWMI 2 2.2 No RWMA, LVH No             -
DM/AWMI 1.3 2 No RWMA,  normal LV function Yes RBBB
SHT/DM/AWMI 2.2 2.5 NoRWMA, LVH+, normal LV function No                  -
DM/AWMI 1.7 1.3 RWMA+, moderate LV dysfunction Yes VPC
SHT/DM/AWMI 1 1.6 No RWMA, normal LV function Yes SVT
DM/AWMI 1.3 2 No RWMA, normal LV function Yes LBBB
CAD/ASMI 2.3 2.4 No RWMA, normal LV function No              -
SHT/IWMI 1.3 1.6 RWMA+, moderate LV dysfunction Yes Sinus Bradycardia
Mg mEq/L Arrhythymia Type of arrhytyhmiaDiagnosis Echo
Day 1 Day 5
Mg mEq/L Arrhythymia Type of arrhytyhmiaDiagnosis Echo
IWMI 1.5 1.7 RWMA+, mild MR, mild LV No                        -
SHT/DM, IWMI 1.2 No RWMA, normal LV function Yes CHB
SHT/DM, Unstable angina 2 2.3 No RWMA, normal LV function No                         -
AWMI 1 1.3 RWMA+, hypokinesia of Yes Torsedes de pointes
DM/IWMI 1.1 1.5 RWMA+, severe LV dysfunction Yes AF
AWMI 1.4 2 No RWMA, normal LV function Yes VPC
SHT/DM/evolved IWMI 1.6 2 No RWMA, normal LV function No                      -
SHT/AWMI 1.1 1.4 RWMA+, severe LV dysfunction Yes SVT
AWMI 1.8 2 No RWMA, normal LV function No                      -
DM/IWMI 1.3 2 Hypokinesia +, RWMA+ Yes Sinus bradycardia
SHT/DM/Ac. AWMI 1.2 1.7 No RWMA, normal LV function Yes PAC
SHT/DM/LWMI 1.4 1.9 No RWMA, normal LV function Yes VPC
SHT/DM/AWMI 2 2.2 No RWMA, normal LV function Yes AF
SHT/DM/AWMI 1.3 1.6 RWMA+, mild LV dysfunction Yes VPC
unstable  angina 2 2.1 No RWMA, normal LV function No                     -
DM/SHT/IWMI 1.8 2.3 RWMA+, severe LV dysfunction No                 -
 
